View in EDS HTML Full Text PDF Full Text

Two-year macular volume assessment in multiple sclerosis patients treated with fingolimod.

Saved in:
Bibliographic Details
Title: Two-year macular volume assessment in multiple sclerosis patients treated with fingolimod.
Authors: d'Ambrosio, Alessandro (AUTHOR), Capuano, Rocco (AUTHOR), Rossi, Settimio (AUTHOR), Bisecco, Alvino (AUTHOR), Lanza, Michele (AUTHOR), Gesualdo, Carlo (AUTHOR), Leocani, Letizia (AUTHOR), Rodegher, Mariaemma (AUTHOR), Filippi, Massimo (AUTHOR), Marino, Clara (AUTHOR), Maimone, Davide (AUTHOR), Tedeschi, Gioacchino (AUTHOR), Simonelli, Francesca (AUTHOR), Gallo, Antonio (AUTHOR)
Source: Neurological Sciences. 2021, Vol. 42 Issue 2, p731-733. 3p. 1 Chart.
Subjects: Multiple sclerosis, Optical coherence tomography, Fingolimod, Patients' attitudes, Visual acuity, Retinal degeneration
Abstract: Background: Fingolimod (FNG) is associated with the development of symptomatic macular edema (ME) in a small subset of multiple sclerosis (MS) patients. By using spectral domain optical coherence tomography (SD-OCT), an increase in the total macular volume (TMV) was rarely detected during the first months of treatment.Objectives: The objective of this study is to assess whether FNG treatment leads to long-term macular changes in a real-life setting.Methods: Sixty RRMS patients starting FNG, according to therapeutic indication, were enrolled at three Italian MS centers and followed for 2 years.Results: The mean TMV did not change between baseline and the follow-up. No patients experienced visual acuity drop during the follow-up.Conclusions: Initiation of FNG in MS is associated with a modest, not significant, increase in macular volume followed by no further significant changes over 2 years, highlighting the good safety profile of such treatment in MS. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
Description
Abstract:<bold>Background: </bold>Fingolimod (FNG) is associated with the development of symptomatic macular edema (ME) in a small subset of multiple sclerosis (MS) patients. By using spectral domain optical coherence tomography (SD-OCT), an increase in the total macular volume (TMV) was rarely detected during the first months of treatment.<bold>Objectives: </bold>The objective of this study is to assess whether FNG treatment leads to long-term macular changes in a real-life setting.<bold>Methods: </bold>Sixty RRMS patients starting FNG, according to therapeutic indication, were enrolled at three Italian MS centers and followed for 2 years.<bold>Results: </bold>The mean TMV did not change between baseline and the follow-up. No patients experienced visual acuity drop during the follow-up.<bold>Conclusions: </bold>Initiation of FNG in MS is associated with a modest, not significant, increase in macular volume followed by no further significant changes over 2 years, highlighting the good safety profile of such treatment in MS. [ABSTRACT FROM AUTHOR]
ISSN:15901874
DOI:10.1007/s10072-020-04802-x